Skip to content
ChickenStockChickenStock
ResearchTEVA
Teva Pharmaceutical Industries logo

Teva Pharmaceutical Industries (TEVA) stock

NYSE

$44.50+1.95%(+0.85)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

102.43x

P/B

6.51x

P/S

3.01x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue decreased 1.9% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 3, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

32 SEC filings
  • Sabag MarkSee "Remarks" · Nov 12, 2026Open-market sale44,710 shares · $2.0M
    Avg. price $44.14180,760 shares held after
  • Sabag MarkSee "Remarks" · Nov 12, 2026Option exercise44,710 shares · $1.6M
    Avg. price $34.9125,470 shares held after
  • Daniell RichardEVP, Europe Commercial · Nov 11, 2026Open-market sale20,003 shares · $856K
    Avg. price $42.801355,755 shares held after
  • Daniell RichardEVP, Europe Commercial · Nov 11, 2026Option exercise20,003 shares · $694K
    Avg. price $34.775,758 shares held after
  • Francis Richard DPresident and CEO · Nov 10, 2026Open-market sale250,000 shares · $10.6M
    Avg. price $42.2367927,529 shares held after
  • Daniell RichardEVP, Europe Commercial · Nov 9, 2026Open-market sale25,000 shares · $1.1M
    Avg. price $42.911655,755 shares held after
  • Weiss AmirChief Accounting Officer · Nov 9, 2026Open-market sale17,289 shares · $744K
    Avg. price $43.036
    Show 3 price lots
    • 9,534 shares × $43.0289$410K
    • 7,093 shares × $43.0349$305K
    • 662 shares × $43.15$29K
  • Daniell RichardEVP, Europe Commercial · Nov 9, 2026Option exercise25,000 shares · $868K
    Avg. price $34.780,755 shares held after
  • Weiss AmirChief Accounting Officer · Nov 9, 2026Option exercise7,755 shares · $269K
    Avg. price $34.720,826 shares held after
  • Sabag MarkSee "Remarks" · Nov 5, 2026Open-market sale46,000 shares · $1.9M
    Avg. price $41.928980,760 shares held after
  • Sabag MarkSee "Remarks" · Nov 5, 2026Option exercise46,000 shares · $1.6M
    Avg. price $34.9126,760 shares held after
  • Bergwerk DovInterim Cheif Legal Officer · Nov 4, 2026Open-market sale26,260 shares · $1.1M
    Avg. price $41.7211,943 shares held after
    Show 2 price lots
    • 17,505 shares × $41.72$730K
    • 8,755 shares × $41.72$365K
  • Bergwerk DovInterim Cheif Legal Officer · Nov 4, 2026Option exercise26,260 shares · $861K
    Avg. price $32.793
    Show 2 price lots
    • 17,505 shares × $34.7$607K
    • 8,755 shares × $28.98$254K
  • MIGNONE ROBERTODirector · Sep 18, 2026Open-market sale367,600 shares · $14.4M
    Avg. price $39.05550 shares held after
  • Savage BrianInterim Chief Legal Officer · Sep 18, 2026Open-market sale7,342 shares · $285K
    Avg. price $38.8471
    Show 3 price lots
    • 4,503 shares × $38.69$174K
    • 2,525 shares × $39.145$99K
    • 314 shares × $38.7038$12K
  • Savage BrianInterim Chief Legal Officer · Sep 18, 2026Option exercise4,503 shares · $156K
    Avg. price $34.715,842 shares held after
  • Weiss AmirChief Accounting Officer · Aug 21, 2026Open-market sale9,445 shares · $355K
    Avg. price $37.617913,071 shares held after
    Show 2 price lots
    • 6,945 shares × $37.6133$261K
    • 2,500 shares × $37.6307$94K
  • Satchi-Fainaro RonitDirector · Aug 21, 2026Open-market sale415 shares · $15K
    Avg. price $37.25111,986 shares held after
  • Weiss AmirChief Accounting Officer · Aug 21, 2026Option exercise2,500 shares · $49K
    Avg. price $19.6115,571 shares held after
  • Lippman EvanEVP, Business Development · Aug 17, 2026Open-market sale18,600 shares · $680K
    Avg. price $36.574825,591 shares held after
  • Zaks Tal ZviDirector · Aug 5, 2026Open-market sale17 shares · $593
    Avg. price $34.865373,247 shares held after
  • Hughes Eric ASee "Remarks" · Aug 3, 2026Open-market sale25,578 shares · $892K
    Avg. price $34.8757134,877 shares held after
  • Jover PlacidSee "Remarks" · Aug 3, 2026Open-market sale12,827 shares · $447K
    Avg. price $34.87576,774 shares held after
  • Hughes Eric ASee "Remarks" · Aug 3, 2026Option exercise52,744 shares
    160,455 shares held after
  • Jover PlacidSee "Remarks" · Aug 3, 2026Option exercise12,827 shares
    19,601 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Teva Pharmaceutical Industries (TEVA) stock information

NYSE

Teva Pharmaceutical Industries (TEVA) is listed on NYSE. Its market capitalization is about $51.9B. On trailing-twelve-month earnings the P/E ratio is 102.43, and the P/B ratio is 6.51. Return on equity is 6.4%. These figures are computed in-house from official filings and are reference information only.

Teva Pharmaceutical Industries — frequently asked questions

What is the P/E ratio of Teva Pharmaceutical Industries (TEVA)?
On a trailing-twelve-month basis, TEVA trades at a P/E ratio of 102.43. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Teva Pharmaceutical Industries?
TEVA has a market capitalization of about $51.9B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.